HealthTab Signs Reseller Agreement With Abbott to Support UK Expansion

HealthTab Signs Reseller Agreement With Abbott to Support UK Expansion

Avricore Health Inc. (TSXV: AVCR, OTC: AVCRF) ("Avricore Health" or the "Company") is pleased to announce the signing of a reseller agreement between HealthTab™ Inc. and Abbott Rapid Dx UK & Ireland.

This agreement provides a foundation for HealthTab to purchase and distribute the Afinion™ 2 and associated tests for diabetes and heart disease screening in community pharmacies in the UK.

"As we've grown in Canada substantially in collaboration with Abbott, we're excited to take this winning model to the UK," said Hector Bremner, CEO of Avricore Health. "We believe the UK is one of the leading jurisdictions to bring more funding for pharmacists to deliver services and that demand for HealthTab will be significant."

HealthTab is currently in over 530 pharmacies in Canada and is leading a move to greater sophistication in point-of-care testing in community pharmacies, bringing high-quality instruments, robust health data management and quality assurance.

UK Healthcare Demands Need Pharmacy

  • It is estimated that there are over 5 million people with undiagnosed hypertension in the UK today.

  • NHS England recently announced £645 million to support increasing access to primary care, including expanding clinical practice in pharmacy, as an essential part of recovering the system's ability to deliver timely service.

  • It's estimated that optimally treating high-risk Atrial Fibrillation patients would prevent over 14,000 strokes over 3 years and save the NHS nearly £242 million.

  • The NHS notes that high cholesterol, along with other factors, is a major factor in heart attack and stroke risk, however, late diagnosis or under-treatment is very common.

  • There are over 13,000 pharmacies in the UK, serving a population of over 67 million people, of which, 96% live within 20 minutes by walking or using transit of a community pharmacy.

About HealthTab

HealthTab is a turnkey point-of-care testing solution that combines best-in-class point-of-care technologies with a secure, cloud-based platform for tackling pressing global health issues.

With just a few drops of blood from a finger prick, the system generates lab-accurate results on the spot and data is reported in real time. The test menu includes up to 23 key biomarkers for screening and managing chronic diseases, such as diabetes and heart disease (e.g., HbA1c, Lipid Profile, eGFR). HealthTab has also recently added capabilities for bacterial and viral tests, such as strep and COVID-19.

The HealthTab network model is unlike anything in pharmacy today. It gives knowledgeable and trusted pharmacists a greater role in primary care delivery, while empowering patients to take more control of their health. It also reduces costs and waiting times and provides many potential revenue streams including equipment leasing & consumables, direct access testing, disease prevention & management programs, sponsored health programs, decentralized clinical trials, real world data (RWD) sets, and third-party app integration through API.

To find a location near you, please visit: healthtab.com/locations

HealthTab Market Fast Facts

  • Point-of-Care Testing Market to reach $50.6 Billion USD in 2025 ( Source )
  • Glucose monitoring (diabetes related) to make up the largest growth within the sector. ( Source )
  • Nearly 13.6 Million Canadians expected to diabetic or prediabetic by 2030, with many undiagnosed ( Source )
  • Over 1 in 3 Americans, approximately 88 million people, have pre-diabetes ( Source )
  • Close to 160,000 Canadians 20 years and older are diagnosed with heart disease each year, often it's only after a heart attack they are diagnosed. ( Source )
  • There are more than 10,000 pharmacies in Canada, 88,000 pharmacies in the US, nearly 12,000 in the UK.

About Avricore Health Inc.

Avricore Health Inc. (TSXV: AVCR) is a pharmacy service innovator focused on acquiring and developing early-stage technologies aimed at moving pharmacy forward. Through its flagship offering HealthTab™ (a wholly owned subsidiary), its mission is to make actionable health information more accessible to everyone by creating the world's largest network of rapid testing devices in community pharmacies.

Contact:

Avricore Health Inc.
Hector Bremner, CEO 604-773-8943
info@avricorehealth.com
www.avricorehealth.com

Cautionary Note Regarding Forward-Looking Statements
Information in this press release that involves Avricore Health's expectations, plans, intentions or strategies regarding the future are forward-looking statements that are not facts and involve a number of risks and uncertainties. Avricore Health generally uses words such as "outlook," "will," "could," "would," "might," "remains," "to be," "plans," "believes," "may," "expects," "intends," "anticipates," "estimate," "future," "positioned," "potential," "project," "remain," "scheduled," "set to," "subject to," "upcoming," and similar expressions to help identify forward-looking statements.

In this press release, forward-looking statements include statements regarding: the completion of the placement and the expected timing thereof and the Company's expected use of proceeds from the placement; the unique features that the HealthTab™ platform offers to pharmacists and patients. Forward-looking statements reflect the then-current expectations, beliefs, assumptions, estimates and forecasts of Avricore Health's management. The forward-looking statements in this press release are based upon information available to Avricore Health as of the date of this press release. Forward-looking statements believed to be true when made may ultimately prove to be incorrect. These statements are not guarantees of the future performance of Avricore Health and are subject to a number of risks, uncertainties and other factors, some of which are beyond its control and may cause actual results to differ materially from current expectations, including without limitation: failure to meet regulatory requirements; changes in the market; potential downturns in economic conditions; and other risk factors described in Avricore's public filings. These forward-looking statements speak only as of the date on which they are made, and the Company undertakes no obligation to update them publicly to reflect new information or the occurrence of future events or circumstances, unless otherwise required to do so by law.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.


Primary Logo

News Provided by GlobeNewswire via QuoteMedia

AVCR:CA
The Conversation (0)
Avricore Health Corporate Update - Company Demonstrates Strong Growth

Avricore Health Corporate Update - Company Demonstrates Strong Growth

Avricore Health INC. (TSXV: AVCR) (the " Company " or " AVCR ") reports on its third quarter results which demonstrate significant growth in pharmacy locations offering HealthTab driving strong revenue growth and operational cashflow positivity. With demand for clinical services growing in pharmacies thanks to the ever-expanding scope and demonstrated success they are having with it; the Company expects to finish the year well ahead of the year previous and have great momentum for 2024.

"Patients and pharmacists are discovering and accessing new information that's having a powerful impact on their care and support thanks to HealthTab," said Hector Bremner, CEO of Avricore Health Inc. "Our ambition of helping more people live better is becoming reality each day and we are poised to make big breakthroughs in bringing this service to more patients around the world."

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
HealthTab Supports Patient Testing in the First Rexall® Pharmacy Walk-In Clinic

HealthTab Supports Patient Testing in the First Rexall® Pharmacy Walk-In Clinic

Avricore Health Inc. (TSXV: AVCR, OTC: AVCRF) ("Avricore Health" or the "Company") is expanding its innovative point-of-care chronic and infectious disease screening and health-data management platform, HealthTab™, further into the Canadian pharmacy ecosystem with one of Canada's largest pharmacy retailers, Rexall Pharmacy Group ULC ("Rexall").

"With Pharmacies' expanded scope and rising patient demand, the need for the clinical pharmacy practice is greater than ever," said Hector Bremner, CEO of Avricore Health. "We're excited to work with Rexall pharmacy teams to support positive patient outcomes through real-time insights into their health."

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
Avricore Health Corporate Update - Mid-Year Review Demonstrates Company on Right Track

Avricore Health Corporate Update - Mid-Year Review Demonstrates Company on Right Track

Avricore Health INC. (TSXV: AVCR) (the " Company " or " AVCR ") continues to achieve significant growth, new partnerships and developing new markets while surpassing margin targets. Now, as the Company looks back at the first half of the year, it continues with confidence on its strategy to bring HealthTab™, its turnkey solution for point of care testing and data management, to more pharmacies across Canada and the world.

"We've had an incredible year so far and we're very excited about what's still to come," said Hector Bremner, CEO of Avricore Health Inc. "Make no mistake, with new partners in Canada and expansion into the UK, we have nothing but blue sky in front of us."

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
Avricore's HealthTab Selected for Feasibility Study for Testing in Community Pharmacies in United Kingdom

Avricore's HealthTab Selected for Feasibility Study for Testing in Community Pharmacies in United Kingdom

Avricore Health Inc. (TSXV: AVCR, OTC: AVCRF) ("Avricore Health" or the "Company") is pleased that HealthTab, the Company's leading pharmacy-based platform for testing and health data management, has been selected by a collaborative involving the internationally renowned Barts Heart Centre and HEART UK to assess the feasibility of community pharmacists in the UK's ability to complement opportunistic blood pressure checks with cholesterol testing to assess overall cardiovascular risk and build on the clinical services offered.

"In the wake of the pandemic, it's clear that the community pharmacy needs to play a bigger role in delivering more access to healthcare services, especially chronic disease screening and management," said Hector Bremner, CEO of Avricore Health. "We are honoured to have been selected for this important project and look forward to working with pharmacist as they support patients with this vital service."

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
HealthTab to Integrate CONTOUR®NEXT Family of Blood Glucose Meters to Offer Deeper Diabetes Patient Insights

HealthTab to Integrate CONTOUR®NEXT Family of Blood Glucose Meters to Offer Deeper Diabetes Patient Insights

Avricore Health Inc. (TSXV: AVCR, OTC: AVCRF) ("Avricore Health" or the "Company") is pleased to announce its agreement with Ascensia Diabetes Care, a global diabetes care company, to integrate their blood glucose monitoring (BGM) systems, marketed as CONTOUR ® NEXT GEN and CONTOUR ® NEXT ONE, with Avricore's pharmacy-based point-of-care testing (POCT) platform, HealthTab. Ascensia Diabetes Care is a subsidiary of PHC Holdings Corporation (TSE 6523).

The partnership's objective is to support patients and pharmacists in Canada in better managing diabetes by linking the daily blood glucose testing results and pattern history data collected via the CONTOUR ® NEXT GEN or CONTOUR ® NEXT ONE meter the patient uses to the patient's HealthTab account. The partnership also seeks to support utilization of each technology by opening discussions related to collaborative communications to ensure patients and pharmacists are able to take advantage of what these data insights offer.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
Ocumetics Announces Offering of up to $4 million of Secured Convertible Debentures

Ocumetics Announces Offering of up to $4 million of Secured Convertible Debentures

(TheNewswire)

Ocumetics Technology Corp.

Calgary, Alberta TheNewswire - May 15, 2024.  Ocumetics Technology Corp. (" Ocumetics " or the " Corporation ") (TSXV: OTC) (OTCQB: OTCFF) (FRA: 2QBO) announces that it proposes to complete a non-brokered private placement of secured convertible debentures having an aggregate face value principal amount of up to $4,000,000 (the " Principal ").  The debentures will be subject to an original issue discount of 6%, resulting in net available funds to the Corporation of up to $3,760,000 (the " Net Proceeds ").   Debentures will bear interest at rate of 18% per annum, compounded annually.  The Debentures will mature, and Principal and interest will be payable by the Corporation, on the date which is two years from the date of issue.  The Corporation may prepay the indebtedness under the debentures at any time upon ninety (90) days prior written notice, without penalty.

News Provided by TheNewsWire via QuoteMedia

Keep reading...Show less
Starlink satellites hovering over telecommunications network.

When is the Starlink IPO Date and Can You Invest? (Updated 2024)

There's been a great deal of speculation surrounding a potential Starlink initial public offering (IPO).

Elon Musk's satellite internet business been referred to by many as the future of global connectivity, offering low latency and high speed in even the most remote locations. To date, the company controls roughly 6,000 satellites and boasts over 2.7 million subscribers, and the idea of an impending Starlink stock release date has investors excited.

The main reason for this interest is Musk's reputation in the investment space. Despite recent pitfalls at X, previously known as Twitter, the man has been involved in multiple highly successful and high-profile tech companies. Starlink itself is an offshoot of one of his other companies, SpaceX.

Keep reading...Show less
ARway SDK 3.1 Unveiled - Revolutionizing Large-Scale, Location-Based Augmented Reality Navigation

ARway SDK 3.1 Unveiled - Revolutionizing Large-Scale, Location-Based Augmented Reality Navigation

Third Major Release in 2024 Marks Dramatic Improvements In Indoor Navigation & Mapping

ARway.ai ("ARway" or the "Company") (CSE:ARWY)(OTCQB:ARWYF)(FSE:E65) is an AI powered Augmented Reality Experience platform with a disruptive no-code, no beacon spatial computing solution enabled by visual marker tracking with centimeter precision is pleased to announce the launch of ARway V3.1, a major update to its spatial computing platform providing augmented reality navigation and immersive experiences. The new V3.1 technology updates and features include major improvements to the range and accuracy of AR experiences across large scale venues and increased speed of deployment of AR indoor navigation experiences. The company believes these major improvements will drive additional revenue and additional global deployments ARway.ai currently has over 5000+ total accounts, with 5400+ maps created and 60+ pilots and trials. Demand for ARway is accelerating in from around the world for various use-cases and industries looking to leverage the Company's augmented reality and spatial computing technology

News Provided by ACCESSWIRE via QuoteMedia

Keep reading...Show less
Closeup of black building with Apple logo on it.

Apple Debuts AI-Powered iPads

At its highly anticipated Let Loose event on Tuesday (May 7), Apple (NASDAQ:AAPL) unveiled new products and updates focused primarily on enhanced performance, display technology and accessories for its iPad lineup.

Read on to learn about the company's new products and how market participants reacted.

Keep reading...Show less
Nextech3D.ai's AI Search Engine Powered by Nvidia GPUs Accelerating It's Production of 3D Models

Nextech3D.ai's AI Search Engine Powered by Nvidia GPUs Accelerating It's Production of 3D Models

New AI Increasing 3D Model production up to 40%

Search engine has over 200,000 3D models with unlimited color and texture variations

News Provided by ACCESSWIRE via QuoteMedia

Keep reading...Show less
Nextech3D.ai Receives Large 3D AI Purchase Order from Blue Chip Enterprise Customer

Nextech3D.ai Receives Large 3D AI Purchase Order from Blue Chip Enterprise Customer

  • Nextech3D.ai Continues to Sign New & Renewal 3D Modeling Deals plus AR Visualization For Enterprise Ecommerce
  • Company Has Expanded into AI CAD-3D Rendering to Capture Larger Market Share

Nextech3D.ai (OTCQX:NEXCF)(CSE:NTAR)(FSE:EP2), a patented 2D-3D Generative AI-Powered 3D model supplier (Patent #11,948,248) for Amazon, Miele, P&G, Kohls, and other major e-commerce retailers is pleased to announce that the Company has received an order for 1,000+ 3D AI models and over 4,000+ 3D AI digital photos in May with delivery set to begin in June with a contract value in the mid-six figures. This large enterprise order is a testament to the company's pioneering AI technologies and expertise in creating 3D models and now renderings of 3D models in 2K, 4K, and 8K for e-commerce enterprise customers across the globe

Nextech3D.ai CEO Evan Gappelberg commented, "This enterprise customer has recognized the significant ROI of 3D models in e-commerce and is now accelerating its purchasing of 3D models. Shopify has reported up to a 93% increase in CTR, a 250% increase in conversions, and a 40% reduction in returns by implementing 3D/AR models on their eCommerce websites. Nextech3D.ai is currently working directly with Amazon, the largest e-commerce marketplace, and some of the world's largest e-commerce retailers including Kohl's. We also offer "one-click integration'' with the largest eCommerce platforms including Shopify, BigCommerce, and WooCommerce, which have rolled out 3D/AR and set the standard for Web 3.0 in e-commerce.

News Provided by ACCESSWIRE via QuoteMedia

Keep reading...Show less

Latest Press Releases

Related News

×